About Us>Medical Advisory Board > Pallav K. Mehta, MD

Pallav K. Mehta, MD

Medical Director, Reimagine Care; Assistant Professor of Medicine, MD Anderson Cancer Center at Cooper

Highlights

Member, LBBC Medical Advisory Board; former member, LBBC board of directors; and speaker, 2023 Conference on Metastatic Breast Cancer
Board certified in medical oncology, hematology, and integrative medicine
Cancer liaison physician to the Commission on Cancer (COC) and chair, Cancer Committee for Redeemer Health

Connect

featured_paragraph

Pallav Mehta, MD, is a medical oncologist/hematologist with expertise and interest in breast cancer and integrative oncology and is board certified in medical oncology, hematology, and integrative medicine with previous board certification in internal medicine.

general_content

Dr. Mehta currently serves as an assistant professor of medicine at Cooper Medical School, Rowan University and as director of integrative oncology and practice development at MD Anderson Cancer Center at Cooper in Camden, New Jersey. He is also chief of the division of hematology/oncology and director of oncology for Redeemer Health in partnership with MD Anderson Cancer Center at Cooper.

In February of 2023, Dr. Mehta accepted a position as the medical director of Reimagine Care, a tech-enabled, human-led startup company transforming the cancer care experience for patients and the care team. He continues to maintain his breast cancer clinic on a more limited basis.

While being published in the medical literature and serving as principal investigator on several active clinical trials, Dr. Mehta also co-authored After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients after Cancer, which provides evidence-based information to patients regarding lifestyle intervention after cancer treatment. The book is an international bestseller and has been translated into 3 languages.

Dr. Mehta has received over 30 Castle Connolly “Top Doc” distinctions regionally and nationally in cancer care, women’s health, breast cancer and integrative oncology.

quote_style_1

The relationship that is developed between a patient and their oncologist is one that is unique in all of medicine. I truly appreciate and enjoy the opportunity to guide my patients through what is often a frightening and life-changing experience. I firmly believe in utilizing standard of care and cutting-edge cancer therapies, while also understanding the importance of the patient as a human being, incorporating topics such as optimizing nutrition or exercise with every patient I meet. I am always grateful that this wonderful profession provides me with personal and professional fulfillment at every level.

Dr. Pallav Mehta

video

3_column_content

Experience & accolades

Expertise

Medical oncology
Hematology

Education

Fox Chase Cancer Center
- Fellowship, Hematology/Oncology
Temple University Hospital
- Internship and Residency, Internal Medicine
Sidney Kimmel Medical College of Thomas Jefferson University
- Doctor of Medicine
New York University
- Bachelor's of Science - Biology

Experience

Reimagine Care (2023 - Present)
- Medical director
Holy Redeemer Hospital and Medical Center (2017 - Present)
- Chief, Division of Hematology/Oncology
- Director, Oncology
MD Anderson Cancer Center at Cooper (2015 - Present)
- Medical Oncologist (Breast Cancer Specialist)
- Director of Integrative Oncology
- Director of Practice Development

Awards & distinctions

Castle Connolly Regional Top Doctors 1^st Edition
Philadelphia Magazine Top Docs (2018, 2019, 2020)
Jersey's Best Magazine Top Doctors (2017, 2018, 2019)
Jersey's Best Magazine Top Doctors for Women's Health (2018)
Jersey's Best Magazine Top Doctors for Cancer (2017, 2018, 2019)

Professional memberships & board positions

Publications

After Cancer Care by Gerald M. Lemole, MD, Pallav K. Mehta, MD, and Dwight L. McKee, MD

contributions_carousel

Contributions

Treatment for metastatic breast cancer

10/14/24 | BY: Douglas Yee, Pallav K. Mehta

The goal of metastatic breast cancer treatment is to manage the disease while limiting side effects. Learn about available treatments and when they are used.

| 22 Min. Read | 4

Targeted therapy for hormone receptor-positive breast cancer

10/14/24 | BY: Sameer Gupta, Pallav K. Mehta

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

| 12 Min. Read | 1

Clinical trials

09/26/24 | BY: LBBC Staff, Pallav K. Mehta

Clinical trials are research studies carried out in people. They evaluate new therapies and compare the new treatments to current ones.

| 13 Min. Read | 1

FDA approval programs

09/26/24 | BY: Pallav K. Mehta

Studying medicine effects takes years. FDA reviews extend the process, but offers programs to expedite vital medicines for those in need.

| 8 Min. Read

Clinical trials for MBC

09/26/24 | BY: Pallav K. Mehta

There are many reasons you might change treatments for metastatic breast cancer. If you and your doctors find that one medicine isn’t right for you anymore, you’ll talk about other therapies that are available.

| 7 Min. Read | 1

HER2-positive or HER2-low

05/28/24 | BY: Pallav K. Mehta

HER2-positive or HER2-low breast cancer is caused by a genetic mutation in the HER2 gene. Learn more about the causes and treatment options for this type of breast cancer.

| 14 Min. Read | 14

HER2-Positive MBC

05/24/24 | BY: Pallav K. Mehta

Learn more about metastatic breast cancer that is HER2-positive and how it can be treated with targeted therapy.

| 7 Min. Read | 1

Biomarker testing

04/15/24 | BY: Pallav K. Mehta

A biomarker is a protein, gene mutation, or other substance that can be tested using a sample of cancer tissue or blood. Biomarker test results can help you and your doctor better understand your cancer and treatment options.

| 22 Min. Read | 2

Hormone receptor-positive MBC

07/26/23 | BY: Pallav K. Mehta

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

| 6 Min. Read | 1

How breast cancer is staged

04/19/23 | BY: Pallav K. Mehta

Breast cancer staging (0-5) describes the extent of the cancer in the breast and body. Learn more about what your staging diagnosis may mean for you.

| 21 Min. Read | 11

Trastuzumab deruxtecan

12/19/22 | BY: Pallav K. Mehta

Trastuzumab deruxtecan (Enhertu) is an antibody drug conjugate approved to treat people with metastatic, HER2-positive, hormone receptor-negative breast cancer that has grown after at least two past treatments.

| 4 Min. Read

Breast cancer treatment timeline

05/24/22 | BY: Pallav K. Mehta

Breast cancer treatment can vary greatly from person to person. Learn more about the average timelines for diagnostics, testing, treatment, and recovery.

| 16 Min. Read | 3

Metastatic breast cancer symptoms

11/12/21 | BY: Pallav K. Mehta

Metastatic breast cancer can cause a range of symptoms, and not every person experiences them in exactly the same way.

| 10 Min. Read | 1

COVID-19 vaccine boosters for people in breast cancer treatment, with Pallav Mehta, MD

08/25/21 | BY: Pallav K. Mehta

Living Beyond Breast Cancer CEO Jean A. Sachs, MSS, MLSP, speaks with medical oncologist Pallav Mehta, MD, about who is eligible for a COVID-19 booster shot, whom to ask if you think you should get a booster, and how medical centers are adapting to recommendations.

| 14 Min. Read

Getting a second opinion

02/26/21 | BY: Pallav K. Mehta

Learn about the process of getting a second opinion on your breast cancer diagnosis and the many reasons it could be helpful on your journey.

| 13 Min. Read | 8

Symptoms

11/12/20 | BY: Pallav K. Mehta

Signs and symptoms are two different things. Learn about the breast cancer indications doctors look for, and why mammograms are so important.

| 8 Min. Read | 5

Healthcare provider perspective: It’s a marathon

08/23/19 | BY: Madison Hughes, Pallav K. Mehta

Pallav K. Mehta, MD, spoke with LBBC about the changes he’s seen in 15 years of treating metastatic hormone receptor-positive breast cancer, and what people should know about their diagnosis and treatment.

| 13 Min. Read

Inflammatory

08/20/19 | BY: Pallav K. Mehta

Inflammatory breast cancer, or IBC, is an aggressive type of invasive breast cancer that usually doesn’t form a lump.

| 8 Min. Read | 5

Being in treatment for life

08/19/19 | BY: Pallav K. Mehta

A diagnosis of metastatic breast cancer is different because it means you will actively deal with breast cancer for the rest of your life.

| 5 Min. Read

Ado-trastuzumab emtansine

07/16/19 | BY: Pallav K. Mehta

Ado-trastuzumab emtansine (Kadcyla) is the targeted therapy trastuzumab (Herceptin) with the chemotherapy medicine emtansine attached. It may also be called T-DM1.

| 5 Min. Read

Lapatinib

03/19/18 | BY: Pallav K. Mehta

Lapatinib (Tykerb) is targeted therapy used with the chemotherapy pill capecitabine (Xeloda) or the aromatase inhibitor letrozole (Femara) to treat HER2-positive metastatic breast cancer.

| 5 Min. Read | 1

DCIS

08/31/15 | BY: Pallav K. Mehta

In ductal carcinoma in situ, also called DCIS, abnormal cells are found in the lining of the milk ducts, the tubes that carry milk to the nipple. It is also called intraductal carcinoma.

| 6 Min. Read | 19

Goals of treatment

08/31/15 | BY: Pallav K. Mehta

The goal of treatment in metastatic breast cancer is to work with your healthcare team to prevent or slow progression of the disease while easing your symptoms and treatment side effects.

| 5 Min. Read | 1

Making treatment decisions throughout your care

08/31/15 | BY: Pallav K. Mehta

| 6 Min. Read

Pallav K. Mehta, MD

Experience & accolades

Contributions

About LBBC

Your Journey

Population Specific

Popular Resources